Evidence map›Paper›PMID 38622330›Full record

Trial reportEye (London, England)2024

Aqueous humour interleukin-6 and vision outcomes with anti-vascular endothelial growth factor therapy.

Yasir Jamal Sepah, Diana V Do, Marina Mesquida, Bann-Mo Day, Steven Blotner, Rubbia Afridi, Muhammad Sohail Halim, Kyu Hong, Eric Wakshull, Sascha Fauser and 4 more

2 registry-linked trialsOpen access · hybridAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Eye (London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
6.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00891735 phase3completednot on this map

A Phase III, Double-masked, Multicenter, Randomized, Active Treatment-controlled Study of the Efficacy and Safety of 0.5 mg and 2.0 mg Ranibizumab Administered Monthly or on an As-needed Basis (PRN) in Patients With Subfoveal Neovascular Age-related Macular Degeneration

TypeinterventionalSponsorGenentech, Inc.Ran2009 to 2012Enrolled1,097ConditionsAge-related Macular DegenerationArmsRanibizumab
NCT01077401 phase2completednot on this map

Ranibizumab for Edema of the Macula in Diabetes: Protocol 3 With High Dose - the READ 3 Study

TypeinterventionalSponsorJohns Hopkins UniversityRan2010 to 2013Enrolled152ConditionsDiabetic Macular EdemaArmsRanibizumab, ranibizumab
3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 20 institutions in 3 countries.

Yasir Jamal SepahByers Eye Institute, Spencer Center for Vision Research, Stanford University, Palo Alto, CA, USA.
Diana V DoByers Eye Institute, Spencer Center for Vision Research, Stanford University, Palo Alto, CA, USA.
Marina MesquidaRoche Pharma Research and Early Development, Basel, Switzerland.
Bann-Mo DayGenentech Inc., South San Francisco, CA, USA.
Steven BlotnerGenentech Inc., South San Francisco, CA, USA.
Rubbia AfridiByers Eye Institute, Spencer Center for Vision Research, Stanford University, Palo Alto, CA, USA.
Muhammad Sohail HalimByers Eye Institute, Spencer Center for Vision Research, Stanford University, Palo Alto, CA, USA.
Kyu HongGenentech Inc., South San Francisco, CA, USA.
Eric WakshullGenentech Inc., South San Francisco, CA, USA.
Sascha FauserRoche Pharma Research and Early Development, Basel, Switzerland.
Ivaylo StoilovGenentech Inc., South San Francisco, CA, USA. stoilovi@gene.com.
Quan Dong NguyenByers Eye Institute, Spencer Center for Vision Research, Stanford University, Palo Alto, CA, USA. ndquan@stanford.edu.ORCID http://orcid.org/0000-0002-6024-8441
HARBOR
READ-3 Investigators
Retina Associates · USCalifornia Retina Consultants · USRetina Consultants of Texas · USTennessee Retina · USEye Care Associates · USOphthalmic Consultants of Long Island · USRetina Institute · USSmith-Kettlewell Eye Research Institute · USThe Retina Center · USUniversity of California San Diego · USAllegheny General Hospital · USBlack Hills Regional Eye Institute · USCleveland Clinic · USCornell University · USDoheny Eye Institute · USJohns Hopkins University · USMedical College of Wisconsin · USNeurosciences Institute · USOcular Surface Center · USPalmetto Retina Center · US

Funding

Genentech (Genentech, Inc.) NA
6 · The paper itself

Abstract

backgroundThis analysis evaluated aqueous humour (AH) interleukin (IL)-6 concentrations and the association between AH IL-6 and visual outcomes in patients with neovascular age-related macular degeneration (nAMD) or diabetic macular oedema (DMO) receiving anti-vascular endothelial growth factor (VEGF) monotherapy.

methodsPost hoc analysis of the multicentre, double-masked, randomised HARBOR (NCT00891735) and READ-3 (NCT01077401) trials. HARBOR enrolled treatment-naïve nAMD patients. READ-3 enrolled treatment-naïve/previously treated DMO patients. HARBOR patients received ranibizumab 0.5 or 2.0 mg monthly or as needed; AH samples were collected at month 2, after two previous intravitreal injections. READ-3 patients received ranibizumab 0.5 or 2.0 mg as needed; AH samples were collected at baseline and months 3, 6, 9, and 12.

main outcome measureassociation between AH IL-6 concentrations and month 24 best-corrected visual acuity (BCVA).

resultsIn both trials (HARBOR, N = 36; READ-3, N = 137), patients with higher AH IL-6 concentrations had worse visual outcomes. HARBOR patients with low AH IL-6 concentrations at month 2 had a mean (95% CI) BCVA change at month 24 of +2.9 (-2.6, 8.3) letters, whereas patients with high AH concentrations had a mean (95% CI) BCVA change of -9.0 (-22.7, 4.7) letters. READ-3 patients with low AH concentrations at baseline had a mean (95% CI) BCVA change at month 12 of +9.3 (7.4, 11.3) letters, whereas patients with high AH concentrations had a mean (95% CI) BCVA change of +5.6 (2.2, 9.1) letters.

conclusionsHigher IL-6 AH concentrations may predict suboptimal visual responses to anti-VEGF monotherapy in patients with nAMD/DMO.

Indexed as

Angiogenesis InhibitorsAqueous HumorDiabetic RetinopathyInterleukin-6Intravitreal InjectionsMacular EdemaRanibizumabVascular Endothelial Growth Factor AVisual AcuityAgedAged, 80 and overDouble-Blind MethodFemaleHumansMaleMiddle AgedAngiogenesis InhibitorsIL6 protein, humanInterleukin-6RanibizumabVascular Endothelial Growth Factor AVEGFA protein, human

Identifiers

PMID38622330
PMCPMC11156666
OpenAlexW4394812183

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.